{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:50:00Z","timestamp":1793814600739,"version":"4.6.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","thegreenjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.radonc.2023.110040","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T23:10:26Z","timestamp":1701385826000},"page":"110040","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Dosimetric predictors of radiation pneumonitis in patients with prior immunotherapy exposure: A multi-institutional analysis"],"prefix":"10.1016","volume":"190","author":[{"given":"Jianping","family":"Bi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongqin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5863-6023","authenticated-orcid":false,"given":"Vivek","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5500-3338","authenticated-orcid":false,"given":"Guang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2023.110040_b0005","first-page":"JCO2201989","article-title":"Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study","author":"Garassino","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.radonc.2023.110040_b0010","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.radonc.2023.110040_b0015","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jtho.2022.09.217","article-title":"Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial","volume":"18","author":"Zhou","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.radonc.2023.110040_b0020","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.radonc.2023.110040_b0025","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.ijrobp.2017.11.041","article-title":"Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma","volume":"100","author":"Chen","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.radonc.2023.110040_b0030","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jtho.2022.10.003","article-title":"Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study","volume":"18","author":"Girard","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.radonc.2023.110040_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.100787","article-title":"Immune-related adverse events as potential surrogates of immune checkpoint inhibitors' efficacy: a systematic review and meta-analysis of randomized studies","volume":"8","author":"Amoroso","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.radonc.2023.110040_b0040","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.779691","article-title":"Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors","volume":"13","author":"Chennamadhavuni","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.radonc.2023.110040_b0045","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.radonc.2023.110040_b0050","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/j.jtho.2018.08.2035","article-title":"Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors","volume":"13","author":"Suresh","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.radonc.2023.110040_b0055","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1007\/s00262-022-03140-5","article-title":"Severe immune-related adverse events of immune checkpoint inhibitors for advanced non-small cell lung cancer: a network meta-analysis of randomized clinical trials","volume":"71","author":"Gu","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.radonc.2023.110040_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103351","article-title":"Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer","volume":"162","author":"Berti","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.radonc.2023.110040_b0065","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.ijrobp.2022.06.068","article-title":"Predictors of Pneumonitis in Combined Thoracic Stereotactic Body Radiation Therapy and Immunotherapy","volume":"114","author":"Korpics","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.radonc.2023.110040_b0070","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ctrv.2016.11.013","article-title":"Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review","volume":"53","author":"Kroeze","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.radonc.2023.110040_b0075","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.ijrobp.2009.06.091","article-title":"Radiation dose-volume effects in the lung","volume":"76","author":"Marks","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.radonc.2023.110040_b0080","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/JTO.0000000000000187","article-title":"Combined analysis of V20, VS5, pulmonary fibrosis score on baseline computed tomography, and patient age improves prediction of severe radiation pneumonitis after concurrent chemoradiotherapy for locally advanced non-small-cell lung cancer","volume":"9","author":"Tsujino","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.radonc.2023.110040_b0085","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ijrobp.2006.07.1337","article-title":"Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT)","volume":"66","author":"Wang","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.radonc.2023.110040_b0090","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00066-019-01552-4","article-title":"Acute severe radiation pneumonitis among non-small cell lung cancer (NSCLC) patients with moderate pulmonary dysfunction receiving definitive concurrent chemoradiotherapy: Impact of pre-treatment pulmonary function parameters","volume":"196","author":"Zhou","year":"2020","journal-title":"Strahlenther. Onkol."},{"key":"10.1016\/j.radonc.2023.110040_b0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0360-3016(98)00196-5","article-title":"Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients","volume":"42","author":"Kwa","year":"1998","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.radonc.2023.110040_b0100","article-title":"Dosimetric Risk Factors for Acute Radiation Pneumonitis in Patients With Prior Receipt of Immune Checkpoint Inhibitors","volume":"12","author":"Bi","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.radonc.2023.110040_b0105","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ijrobp.2009.09.040","article-title":"Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues","volume":"76","author":"Bentzen","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.radonc.2023.110040_b0110","article-title":"Clinical and dosimetric factors for symptomatic radiation pneumonitis after stereotactic body radiotherapy for early-stage non-small cell lung cancer","volume":"41","author":"Kita","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.110040_b0115","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.lungcan.2008.12.016","article-title":"Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus","volume":"66","author":"Song","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2023.110040_b0120","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.21037\/tlcr-20-523","article-title":"Is clinical target volume necessary?-a failure pattern analysis in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy using intensity-modulated radiotherapy technique","volume":"9","author":"Zou","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.radonc.2023.110040_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109505","article-title":"Feasibility of omitting the clinical target volume under PET-CT guidance in unresectable stage III non-small-cell lung cancer: A phase II clinical trial","volume":"181","author":"Cui","year":"2023","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.radonc.2023.110040_b0130","first-page":"11","article-title":"Radiotherapy and Immunotherapy in Lung Cancer","author":"Hsieh","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.radonc.2023.110040_b0135","article-title":"Effect of Sequence of Radiotherapy Combined With Immunotherapy on the Incidence of Pneumonitis in Patients With Lung Cancer: A Systematic Review and Network Meta-Analysis","author":"Mi","year":"2023","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.radonc.2023.110040_b0140","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.chest.2017.04.177","article-title":"Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials","volume":"152","author":"Khunger","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.radonc.2023.110040_b0145","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s12916-020-01718-3","article-title":"Radiation recall pneumonitis induced by PD-1\/PD-L1 blockades: mechanisms and therapeutic implications","volume":"18","author":"Teng","year":"2020","journal-title":"BMC Med."},{"key":"10.1016\/j.radonc.2023.110040_b0150","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.radonc.2021.01.001","article-title":"Incidence, risk factors, and CT characteristics of radiation recall pneumonitis induced by immune checkpoint inhibitor in lung cancer","volume":"157","author":"Cousin","year":"2021","journal-title":"Radiother. Oncol."}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023093477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023093477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T09:09:57Z","timestamp":1734253797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814023093477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":30,"alternative-id":["S0167814023093477"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2023.110040","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dosimetric predictors of radiation pneumonitis in patients with prior immunotherapy exposure: A multi-institutional analysis","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2023.110040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110040"}}